Inventiva (NASDAQ:IVA) Trading 6.8% Higher – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was up 6.8% on Tuesday . The company traded as high as $4.10 and last traded at $4.1640. Approximately 1,025,597 shares were traded during mid-day trading, an increase of 75% from the average session volume of 587,467 shares. The stock had previously closed at $3.90.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on IVA shares. Wall Street Zen cut shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial started coverage on shares of Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Up 8.5%

The stock’s 50 day moving average price is $4.50 and its two-hundred day moving average price is $5.32.

Institutional Investors Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP acquired a new position in Inventiva during the first quarter worth $1,111,000. Virtu Financial LLC bought a new stake in Inventiva during the 4th quarter valued at approximately $60,000. ADAR1 Capital Management LLC acquired a new stake in shares of Inventiva in the fourth quarter worth $12,601,000. XTX Topco Ltd bought a new position in shares of Inventiva during the 4th quarter worth about $84,000. Finally, Yu Fan acquired a new position in Inventiva in the 4th quarter valued at approximately $6,975,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.